Drug Profile


Alternative Names: Latuda; Lurasidone HCl; Lurasidone hydrochloride; SM-13496; SMP-13496

Latest Information Update: 22 Jun 2017

Price : $50

At a glance

  • Originator Dainippon Sumitomo Pharma
  • Developer DKSH Singapore; DKSH Thailand; Standard Chemical & Pharmaceutical Company; Sumitomo Dainippon Pharma; Sunovion Pharmaceuticals; Takeda
  • Class Antipsychotics; Cyclohexanes; Isoindoles; Piperazines; Small molecules; Thiazoles
  • Mechanism of Action Dopamine D2 receptor antagonists; Serotonin 1A receptor agonists; Serotonin 2A receptor antagonists; Serotonin 2C receptor antagonists; Serotonin 7 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Bipolar depression; Schizophrenia
  • Preregistration Bipolar disorders
  • Phase III Autistic disorder; Major depressive disorder
  • Phase I Psychiatric disorders

Most Recent Events

  • 09 Jun 2017 Sumitomo Dainippon Pharma announces intention to submit application for approval in Japan in financial year 2019
  • 09 Jun 2017 Efficacy and adverse events data from a phase III trial in Bipolar depression released by Sumitomo Dainippon Pharma
  • 22 May 2017 Positive efficacy and adverse events data from a phase III trial in Bipolar depression (In adolescents, In children, Monotherapy) released by Sunovion Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top